1179 Planned Subtotal Resection of Sub-Glioblastoma Followed By LITT Is a Safe and Effective Alternative to Surgical Excision With Intent for Gross Total Resection of Subcortical Glioblastomas (Sub-Glioblastoma)
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
INTRODUCTION: Despite its inherent limitations, ex vivo drug testing remains a powerful tool for personalizing oncologic care. Here, we analyzed the ex vivo drug sensitivity of 151 clinical glioblastoma samples (isocitrate dehydrogenase wild-type) to construct a comprehensive atlas, laying the groundwork for future therapeutic strategies. METHODS: Resected glioblastoma samples were processed into 3D spheroid cultures and exposed to thirteen drugs, including DNA-damaging agents (lomustine, carboplatin, temozolomide, procarbazine, irinotecan, etoposide) and targeted agents (abemaciclib, dabrafenib, osimertinib, rucaparib, trametinib). Therapeutic responses were dichotomized into drug sensitivity or resistance. RESULTS: The drug sensitivity atlas comprised 99 newly diagnosed glioblastomas (n-glioblastoma) and 52 recurrent glioblastomas (r-glioblastoma). Regarding the DNA-damaging agents, both n- and r-glioblastomas were highly refractory to lomustine, with 90% of n- and r-glioblastomas showed procarbazine sensitivity. For the targeted agents, a high proportion (>90%) of n- and r-glioblastomas were sensitive to rucaparib. There was no difference in the proportion of n- and r-glioblastomas (4-53%) sensitive to the remaining agents. in n-glioblastomas (43% of n-glioblastomas), temozolomide sensitivity correlated with lomustine, irinotecan, etoposide, abemaciclib, and osimertinib (p = 0.047, 0.035, 0.003, 0.019, and 0.018, respectively). Additionally, irinotecan sensitivity correlated with abemaciclib sensitivity (p = 0.019). These correlations were not seen in r-glioblastomas, suggesting cancer evolution in response to therapy. Consistent with this interpretation, notable changes in drug sensitivity profiles were observed when serial samples were analyzed. CONCLUSIONS: An atlas of ex vivo drug sensitivity in glioblastoma revealed distinct, non-random patterns, highlighting potential therapeutic vulnerabilities that inform future focused ultrasound and drug combination clinical trials.
Fields of Study & Subjects
Glioma Diagnosis and Treatment
Ovarian cancer diagnosis and treatment
Epilepsy research and treatment
Publication details
- Journal / source
- Neurosurgery
- Volume
- 72
- Issue
- Supplement_1
- Pages
- 229–229
- Publication date
- 26 March 2026
- Language
- EN